"The U.S. Food and Drug Administration today approved the Gastric Emptying Breath Test (GEBT), a new non-invasive test to aid in the diagnosis of delayed gastric emptying, known as gastroparesis.
Current tests used to diagnose gastroparesis "...
The natural digestive enzymes in VIOKASE® (pancrelipase tablets, powder) hydrolyze fats into fatty acids and glycerol, split protein into amino acids, and convert carbohydrates to dextrins and short chain sugars.
Under conditions of the USP test method (in vitro) VIOKASE® (pancrelipase tablets, powder) has the following total digestive capacity:
| VIOKASE® Powder
Each 0.7 g (1/4 Teaspoonful)
|Dietary fat, grams||28||56||59|
|Dietary protein, grams||30||60||70|
|Dietary starch, grams||30||60||70|
VIOKASE® (pancrelipase tablets, powder) 8 Tablets are 468 mg immediate release tablets and are not enteric-coated. VIOKASE® (pancrelipase tablets, powder) 16 Tablets are 935 mg immediate release tablets and are not enteric-coated.
Last reviewed on RxList: 12/9/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Viokase Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.